CILIBERTO, GIADA
 Distribuzione geografica
Continente #
NA - Nord America 133
EU - Europa 93
AS - Asia 9
Totale 235
Nazione #
US - Stati Uniti d'America 133
IE - Irlanda 45
SE - Svezia 24
IT - Italia 11
DE - Germania 7
SG - Singapore 4
CN - Cina 3
FI - Finlandia 3
PL - Polonia 2
VN - Vietnam 2
AT - Austria 1
Totale 235
Città #
Chandler 55
Dublin 45
Nyköping 16
Ashburn 8
Princeton 7
Bremen 6
Medford 6
Des Moines 5
Catania 4
Castellammare Di Stabia 3
Helsinki 3
Santa Clara 3
Seattle 3
Dong Ket 2
Singapore 2
Warsaw 2
DeKalb 1
Messina 1
Munich 1
Nanchang 1
Vienna 1
Wilmington 1
Yicheng 1
Totale 177
Nome #
Axitinib after Sunitinib in metastatic renal cancer: Preliminary results from Italian "Real-World" SAX Study 52
Role of DNA repair machinery and p53 in the testicular germ cell cancer: A review 50
Metabolic syndrome, endocrine disruptors and prostate cancer associations: Biochemical and pathophysiological evidences 39
Correction: Metabolic syndrome, endocrine disruptors and prostate cancer associations: Biochemical and pathophysiological evidences [Oncotarget, 8, (2017) (30606-30616)] doi 10.18632/oncotarget.16725 35
Corrigendum: Pazopanib in metastatic renal cancer: A "real-world" experience at national cancer institute "Fondazione G. Pascale" [Front. Pharmacol., 7, 287, (2016)] doi: 10.3389/fphar.2016.00287 31
Pazopanib in metastatic renal cancer: A "real-world" experience at National Cancer Institute "Fondazione G. Pascale" 28
Deconvolution of malignant pleural effusions immune landscape unravels a novel macrophage signature associated with worse clinical outcome in lung adenocarcinoma patients 10
Totale 245
Categoria #
all - tutte 1.637
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 1.637


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202122 0 0 0 0 0 0 0 12 5 2 0 3
2021/202235 0 0 0 0 2 0 3 1 0 2 8 19
2022/2023150 8 14 5 17 15 15 0 8 63 2 3 0
2023/202431 1 5 0 7 1 2 0 3 0 0 8 4
2024/20257 1 6 0 0 0 0 0 0 0 0 0 0
Totale 245